Share this video  

ASCO 2022 | ctDNA and late recurrence in high-risk, HR+, HER2- breast cancer

Marla Lipsyc-Sharf, MD, Dana-Farber Cancer Institute, Boston, MA, discusses results of a study evaluating circulating tumor DNA (ctDNA) and late recurrence in high-risk, hormone receptor–positive, HER2-negative breast cancer. Of the 83 evaluable patients, 10% had detectable ctDNA more than 5 years after initial diagnosis. In addition, 6 patients developed distant metastatic recurrence, all 6 of which also tested positive for ctDNA prior to distant metastatic recurrence with a median lead time of 12.4 months. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.